OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologicsBusiness Overview: OSSPL is a subsidiary of Strides Pharma Ltd. The...
The provided document is an "Intimation of Investor Presentation," which announces that an investor meeting was held and the investor presentation has been uploaded to the company's website. As the actual content of the investor presentation (details on business performance, growth drivers, financials, etc.) is not included in this document,...
OneSource Specialty Pharma reported a strong Q4FY26! Revenue jumped 47% QoQ to ₹42.82 Cr, and EBITDA soared 5x+ to ₹9.19 Cr, with adjusted profit (PAT) turning positive at ₹3.90 Cr. Full-year FY26 saw a 2% dip in revenue to ₹142.16 Cr and a 35% decline in EBITDA to ₹30.42 Cr,...
OneSource Specialty Pharma faced a challenging Q3FY26, with revenue dropping 26% YoY to ₹290.3 Cr and EBITDA plunging 88% YoY to ₹17.3 Cr. This resulted in an adjusted PAT loss of ₹47.2 Cr, primarily due to delays in Canadian customer approvals for semaglutide and largely fixed operating costs. Despite the...
OneSource Specialty Pharma reported strong Q2FY26 results. Revenue grew 12% YoY to ₹375.8 Cr, driven by new Master Service Agreements (MSAs) and its established IP-led base business. EBITDA jumped 37% YoY to ₹106.5 Cr, with margins improving to 28%. Adjusted PAT reached ₹44.9 Cr, marking a turnaround from previous losses....
1. Financial Highlights: No financial data or margin trends were disclosed. 2. Strategic Initiatives & Growth Drivers: No updates on new launches, expansions, or capital expenditure plans. 3. Business Developments: Audio and video recordings of the recent earnings call have been made available for investors and analysts. 4. Market Position...
